Research Article
COVID-19 Vaccination Intention and Vaccine Hesitancy among Patients with Autoimmune and Autoinflammatory Rheumatological Diseases: A Survey
Table 2
Clinical and therapeutic data of the AIIRD population according to their decision regarding the COVID-19 vaccine (n = 206).
| | Variables, median (min-max) or n (%) | Total (n = 206) | COVID-19 vaccine acceptant group (n = 145) | COVID-19 vaccine hesitant group (n = 33) | COVID-19 vaccine resistant group (n = 28) | |
| | AIIRD subtype | | | | | 0.749 | | SLE | 85 (41.3) | 61 (42.1) | 12 (36.4) | 12 (42.9) | | | RA | 54 (26.2) | 38 (26.2) | 7 (21.2) | 9 (32.1) | | | SSc | 29 (14.1) | 20 (13.8) | 4 (12.1) | 5 (17.9) | | | BD | 22 (10.7) | 18 (12.4) | 4 (12.1) | 0 | | | Primary APLs | 3 (1.5) | 2 (1.4) | 1 (3) | 0 | | | AS | 3 (1.5) | 1 (0.7) | 1 (3) | 1 (3.6) | | | DM | 2 (1) | 1 (0.7) | 0 | 1 (3.6) | | | PsA | 1 (0.5) | 1 (0.7) | 0 | 0 | | | Vasculitis | 1 (0.5) | 1 (0.7) | 0 | 0 | | | AOSD | 1 (0.5) | 1 (0.7) | 0 | 0 | | | Overlap syndrome (SLE, RA) | 5 (2.4) | 1 (0.7) | 4 (12.1) | 0 | | | Disease duration (years) | 5 (0.5–35) | 5 (0.5–28) | 5 (0.5–35) | 8 (0.5–19 | 0.477 | | Self-rated overall disease activity | 6 (0–10) | 6 (0–10) | 6 (0–10) | 5 (0–10) | 0.381 | | Associated comorbidities | | | | | | | Diabetes mellitus | 19 (9.2) | 13 (9) | 5 (15.2) | 1 (3.6) | 0.293 | | Hypertension | 45 (21.8) | 30 (20.7) | 11 (33.3) | 4 (14.3) | 0.167 | | Chronic lung disease | 18 (8.7) | 13 (9) | 3 (9.1) | 2 (3.1) | 0.95 | | Ischemic heart disease | 2 (1) | 2 (1.4) | 0 | 0 | 0.655 | | Others | 56 (27.2) | 39 (26.9) | 11 (33.3) | 6 (21.4) | 0.577 | | History of COVID-19 | 53 (25.7) | 42 (29) | 3 (9.1) | 8 (28.6) | 0.057 | | Hospitalization | 8 (15.1) | 6 (14.3) | 1 (33.3) | 1 (12.5) | 0.629 | | ICU admission | 3 (5.7) | 2 (4.8) | 1 (33.3) | 0 | 0.079 | | COVID-19 among relatives or friends | 84 (40.8) | 55 (37.9) | 16 (48.5) | 13 (46.4) | 0.478 | | Hospitalization | 40 (19.4) | 22 (15.2) | 10 (30.3) | 8 (28.6) | 0.067 | | Death | 23 (11.2) | 14 (9.7) | 6 (18.2) | 3 (10.7) | 0.389 | | Therapeutic data | | | | | | | Corticosteroids | 138 (67) | 101 (69.7) | 20 (60.6) | 17 (60.7) | 0.457 | | Hydroxychloroquine | 94 (45.6) | 64 (44.1) | 19 (57.6) | 11 (39.3) | 0.291 | | Leflunomide | 22 (10.7) | 17 (11.7) | 2 (6.1) | 3 (10.7) | 0.638 | | Methotrexate | 66 (32) | 50 (34.5) | 7 (21.2) | 9 (32.1) | 0.339 | | Mycophenolate mofetil | 42 (20.4) | 29 (20) | 7 (21.2) | 6 (21.4) | 0.977 | | Adalimumab | 4 (1.9) | 3 (2.1) | 1 (3) | 0 | 0.681 | | Infliximab | 4 (1.9) | 1 (0.7) | 2 (6.1) | 1 (3.6) | 0.105 | | Etanercept | 4 (1.9) | 2 (1.4) | 2 (6.1) | 0 | 0.156 | | Golimumab | 1 (0.5) | 1 (0.7) | 0 | 0 | 0.810 | | Tocilizumab | 1 (0.5) | 1 (0.7) | 0 | 0 | 0.810 | | Secukinumab | 1 (0.5) | 1 (0.7) | 0 | 0 | 0.810 | | Rituximab | 2 (1) | 1 (3) | 1 (3.6) | 0 | 0.09 | | Adherence to therapy | 175 (85) | 126 (86.9) | 26 (78.8) | 23 (82.1) | 0.388 |
|
|
AOSD: adult-onset Still’s disease, APLs: antiphospholipid syndrome, AS: ankylosing spondylitis, BD: Behcet’s disease, DM: dermatomyositis, PsA: psoriatic arthritis, RA: rheumatoid arthritis, SLE: systemic lupus erythematosus, SSc: systemic sclerosis.
|
